The Johannes Gutenberg University of Mainz is a university in Mainz, Rhineland Palatinate, Germany, named after the printer Johannes Gutenberg. With approximately 36,500 students in about 150 schools and clinics, it is among the ten largest universities in Germany. Starting on 1 January 2005 the university was reorganized into 11 faculties of study. Wikipedia.
Walther A.,RWTH Aachen |
Muller A.H.E.,Johannes Gutenberg University Mainz
Chemical Reviews | Year: 2013
Some of the advancements in the field of non-centrosymmetric Janus particles (JP) along with the synthesis, self-assembly behavior, physical properties, and applications, are discussed. Researchers focus on describing biological, biobased, and bioinspired JPs, access routes based on classical organic synthesis, along with macromolecular engineering and self-assembly of polymers, symmetry breaking at interfaces, selective growth of second compartments, and symmetry-breaking in confined volumes. The researchers also discuss related techniques using the break-up or patterning of side-by-side flown liquids, and miscellaneous techniques. They inform that significant progress has been made in diversifying synthetic strategies for the preparation of JPs over a period of time with the aim to include diverse functionalities, target inorganic or organic hybrid materials, along with finding ways toward a scale-up. Source
Johannes Gutenberg University Mainz | Date: 2015-03-18
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2015-01-23
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
Ganymed Pharmaceuticals and Johannes Gutenberg University Mainz | Date: 2015-01-27
The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
BioNTech AG and Johannes Gutenberg University Mainz | Date: 2014-12-16
The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.